Part D Makes Payors Allies of Pharma Against Price Controls
This article was originally published in RPM Report
Executive Summary
Medicare prescription drug plan sponsors don't want the government to take over the market any more than Big Pharma does. Can insurers and manufactuers work together to block interference in the new drug benefit?
You may also be interested in...
Negotiating Price Negotiation: Why the Democrats Will Struggle to Pressure Part D Prices
The new Congress wants to make federal price negotiation under Medicare a reality. But it won't be easy. Big Pharma should expect plenty of interference from the Democrats in Part D, but it is hard to see a meaningful impact on prices in the near term.
Tsunami Economics: The Wave is Coming
The US faces a fiscal tidal wave on the horizon. Reforming Medicare Part D may be one way of escaping it. Government Accountability Office Director David Walker preaches a stern warning.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.